Harbor Capital Advisors Inc. Has $3.74 Million Holdings in Cabot Co. (NYSE:CBT)

Harbor Capital Advisors Inc. grew its stake in Cabot Co. (NYSE:CBT - Free Report) by 48.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 33,444 shares of the specialty chemicals company's stock after purchasing an additional 10,852 shares during the period. Harbor Capital Advisors Inc. owned approximately 0.06% of Cabot worth $3,738,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of CBT. Farther Finance Advisors LLC raised its stake in Cabot by 197.9% during the third quarter. Farther Finance Advisors LLC now owns 417 shares of the specialty chemicals company's stock worth $47,000 after acquiring an additional 277 shares in the last quarter. New York State Common Retirement Fund increased its position in shares of Cabot by 16.1% during the 3rd quarter. New York State Common Retirement Fund now owns 259,378 shares of the specialty chemicals company's stock worth $28,991,000 after purchasing an additional 36,036 shares in the last quarter. US Bancorp DE lifted its holdings in Cabot by 0.9% during the 3rd quarter. US Bancorp DE now owns 30,485 shares of the specialty chemicals company's stock valued at $3,407,000 after purchasing an additional 267 shares during the last quarter. First Trust Direct Indexing L.P. bought a new stake in Cabot during the third quarter worth about $203,000. Finally, Pathway Financial Advisers LLC increased its holdings in shares of Cabot by 11,108.7% during the third quarter. Pathway Financial Advisers LLC now owns 7,734 shares of the specialty chemicals company's stock worth $864,000 after buying an additional 7,665 shares in the last quarter. 93.18% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Cabot news, CFO Erica Mclaughlin sold 23,274 shares of the company's stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $99.79, for a total value of $2,322,512.46. Following the completion of the sale, the chief financial officer now owns 59,814 shares of the company's stock, valued at approximately $5,968,839.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CFO Erica Mclaughlin sold 23,274 shares of the business's stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $99.79, for a total value of $2,322,512.46. Following the completion of the transaction, the chief financial officer now directly owns 59,814 shares in the company, valued at approximately $5,968,839.06. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Sean D. Keohane sold 25,617 shares of the firm's stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $101.55, for a total transaction of $2,601,406.35. Following the sale, the chief executive officer now owns 331,174 shares in the company, valued at $33,630,719.70. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,939 shares of company stock worth $7,308,812. Insiders own 3.07% of the company's stock.

Wall Street Analyst Weigh In

CBT has been the topic of a number of research analyst reports. UBS Group decreased their price target on Cabot from $103.00 to $98.00 and set a "neutral" rating on the stock in a research report on Tuesday, August 6th. JPMorgan Chase & Co. lifted their price target on Cabot from $95.00 to $105.00 and gave the company a "neutral" rating in a report on Wednesday, August 7th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus target price of $101.75.

Cabot Trading Up 1.0 %

Shares of CBT stock traded up $1.07 on Monday, reaching $110.09. 709,864 shares of the stock were exchanged, compared to its average volume of 336,001. The stock has a 50 day moving average price of $108.20 and a 200 day moving average price of $100.87. The stock has a market cap of $6.04 billion, a PE ratio of 13.15, a P/E/G ratio of 0.90 and a beta of 1.20. Cabot Co. has a one year low of $66.02 and a one year high of $117.14. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.22 and a quick ratio of 1.45.

Cabot (NYSE:CBT - Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The specialty chemicals company reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1 billion. Cabot had a net margin of 12.05% and a return on equity of 26.99%. Cabot's revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.42 EPS. Equities research analysts forecast that Cabot Co. will post 7.07 EPS for the current fiscal year.

Cabot Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.